Mary Smrekar

Learn More
OBJECTIVE Preclinical models in an ovarian cancer cell line (A2780) demonstrate synergistic activity with the combination of gemcitabine and cisplatin compared to either single agent alone. Platinum resistance is related to expression of excision repair proteins, one of which (ERCC-1) has been identified as playing a critical role in the synergy of(More)
OBJECTIVE The goal of this study was to evaluate the tolerance and effectiveness of carboplatin rechallenge using a prolonged desensitizing carboplatin infusion regimen in patients with clinically documented moderate-severe carboplatin hypersensitivity. METHOD Patients admitted for carboplatin infusion were identified by computerized pharmacy records and(More)
OBJECTIVES Although the combination of paclitaxel and carboplatin has a better therapeutic index than the combination of paclitaxel and cisplatin, peripheral neuropathy often occurs and remains the most chronic toxicity of this therapy. CASE Six patients with ovarian or peritoneal carcinoma who developed grade 2 peripheral neuropathy during chemotherapy(More)
OBJECTIVES The feasibility, safety, and preliminary efficacy of a second-line combination therapy for oral topotecan and pegylated liposomal doxorubicin in patients with platinum-resistant or refractory epithelial ovarian, peritoneal, or tubal carcinoma were investigated in this phase I trial. METHODS A fixed dose of oral topotecan 2.3 or 1.53 mg/m(2) on(More)
OBJECTIVE Topotecan and carboplatin are active in relapsed ovarian cancer, but attempts to combine these agents are limited by myelotoxicity. This phase I/II trial combined weekly topotecan, which is less myelosuppressive than the standard 5-day regimen, with carboplatin in patients with potentially platinum-sensitive relapsed ovarian or peritoneal(More)
5147 Background: Topotecan is an active second-line agent for ovarian cancer but combinations with carboplatin have been limited by myeolsuppression. Weekly topotecan has been associated with less myelosuppression and moderate activity. We performed a phase I trial of weekly topotecan and carboplatin in potentially platinum sensitive ovarian and peritoneal(More)
OBJECTIVE Paclitaxel administered weekly in equal cumulative doses is associated with less hematologic and non-hematologic toxicity than an every 3-week administration. We studied weekly paclitaxel and 3-week carboplatin in potentially platinum-sensitive recurrent ovarian and peritoneal carcinoma. METHODS Paclitaxel at a dose of 80 mg/m(2) over 1 h in(More)
  • 1